BMRN Q1 2019 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$401M+7.3% YoY

Gross Profit

$312M77.7% margin

Operating Income

-$54M-13.5% margin

Net Income

-$56M-14.1% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

+13.5%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$84M

Stock-Based Comp.

$43M

Balance Sheet

Total Assets

$4.4B

Total Liabilities

$1.5B

Stockholders' Equity

$2.9B

Cash & Equivalents

$364M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$401M	$373M	+7.3%
Gross Profit	$312M	$291M	+7.0%
Operating Income	-$54M	-$44M	-21.6%
Net Income	-$56M	-$44M	-27.9%

Revenue Segments

Product

$394M50%

Product Four

$126M16%

Product Three

$107M14%

Product Two

$87M11%

Product One

$45M6%

Product Seven

$12M2%

Product Six

$12M2%

Product Five

$5M1%

Geographic Segments

UNITED STATES

$191M48%

Europe

$125M31%

Rest Of World

$51M13%

Latin America

$34M8%